Overview

A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant

Status:
Active, not recruiting

Trial end date:
2025-06-25

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the effect of ixazomib citrate maintenance therapy on progression-free survival (PFS), compared to placebo, in participants with newly diagnosed multiple myeloma (NDMM) who have had a response (complete response [CR], very good partial response [VGPR], or partial response [PR]) to induction therapy followed by high-dose therapy (HDT) and autologous stem cell transplant (ASCT).

Phase:

Phase 3

Details

Lead Sponsor:

Millennium Pharmaceuticals, Inc.

Treatments:

Citric Acid
Glycine
Ixazomib